Search Results
Mar 05, 2026, 12:25 ET Shared origins illuminate potential dependency across brain tumor types
cohort of rare tumor samples from 38 patients and compared it to normal pineal gland development. By measuring gene expression using single-cell RNA-sequencing, they found that a population of early cells called pinealocyte progenitors is the most similar to these tumors, implicating their role in pineoblastoma
More news about: St. Jude Children's Research Hospital
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
available treatment options.About Therna BiosciencesTherna is a biotechnology company redefining RNA therapeutics by uniting deep RNA biology with state-of-the-art RNA foundation models and generative AI. Its biology-guided platform enables rapid, end-to-end design of precisely engineered
More news about: Therna Biosciences
Mar 05, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Mar 05, 2026, 03:00 ET Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence
AI-powered immune intelligence platform designed to decode the systemic immune response longitudinally from simple blood samples. By analyzing immune-derived RNA using advanced machine learning, the platform transforms complex liquid biopsy data into clinically actionable insights. The platform supports tracking
More news about: Novigenix AI
Mar 04, 2026, 21:01 ET Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
Transcriptomic Insights: Research titled "Transcriptomic Evidence of AJ201 Target Engagement and Biological Response in SBMA Muscle" utilized RNA-seq to demonstrate that AJ201 engages the Nrf2 antioxidant pathway. The data confirmed that treatment modulates multiple biological axes rather than
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 04, 2026, 20:31 ET Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
Transcriptomic Insights: Research titled "Transcriptomic Evidence of AJ201 Target Engagement and Biological Response in SBMA Muscle" utilized RNA-seq to demonstrate that AJ201 engages the Nrf2 antioxidant pathway. The data confirmed that treatment modulates multiple biological axes rather than
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 04, 2026, 18:01 ET Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight
Developmental Activities in the Nanomedicine MarketIn February 2026, scientists at Newark developed a first-of-its-kind RNA-based nanotechnology that assembles itself inside living human cells and can be programmed to stop the propagation of harmful cells. The findings, recently
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 17:46 ET H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
quadruple therapy, including in antibiotic-resistant strains. Its differentiation lies in a single-molecule dual mechanism combining rifamycin-mediated RNA polymerase inhibition with nitroimidazole-induced DNA damage, providing intrinsic synergy, greater potency, and lower resistance risk without added regimen
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 10:06 ET Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular
More news about: Codexis
Mar 04, 2026, 08:00 ET Minaris Launches AgentSCREEN Adventitious Virus Detection by NGS to Simplify Viral Safety Testing for Cell Banks and Cell-Based Samples
approach with a predictable 28-day turnaround time. The assay examines all messenger RNA (mRNA) in a cell bank sample for the presence of viral RNA transcripts and is designed to detect active viral infections from RNA and DNA viruses. A custom GAMP 5 validated bioinformatics pipeline compares sequencing
More news about: Minaris Advanced Therapies
Mar 04, 2026, 07:00 ET Matricelf Ltd. (TASE: MTLF) Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile of Its Personalized Spinal Cord Implant
international regulatory standards, including requirements of the US FDA.Advanced Single Nucleus RNA Sequencing AnalysisMatricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the
More news about: Matricelf Ltd.
Mar 03, 2026, 14:36 ET Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.
offering platform-agnostic solutions for solid tumor and blood cancer research.November 2025 – Pairidex: Introduced FusionMRD, a personalized RNA-based digital PCR assay for monitoring measurable residual disease (MRD) in fusion-driven hematologic malignancies, reporting 0.001% sensitivity using
More news about: Credence Research Inc.
Mar 03, 2026, 10:00 ET Pillar Biosciences Launches oncoReveal® Rapid AML Panel to Support Rapid, Guideline‑Informed Genomic Insights for Acute Myeloid Leukemia
coverage across the CEBPA coding regionFits into heme workflowsProtocols harmonized across Pillar heme DNA and RNA panels to support concurrent processingAML incidenceIn the United States, the American Cancer Society estimates that approximately
More news about: Pillar Biosciences, Inc.
Mar 03, 2026, 09:00 ET REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use.Footprint-free proprietary RNA reprogramming to generate StemRNA™ Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements.US-generated StemRNA Clinical Seed Clones supported
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use.Footprint-free proprietary RNA reprogramming to generate StemRNA™ Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements.US-generated StemRNA Clinical Seed Clones supported
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors
protein misfolding."Dr. Maraganore was the founding CEO and a Director of Alnylam Pharmaceuticals from 2002 to 2021, leading the company from early RNA interference (RNAi) research to the global approval and commercialization of its first five RNAi medicines: ONPATTRO®, GIVLAARI®, OXLUMO®, Leqvio®, and
More news about: Protego Biopharma
Mar 03, 2026, 09:00 ET REPROCELL startet GMP Master Cell Bank-Produktion für klinische iPSCs
Spendern erfüllen die Anforderungen der FDA, EMA und PMDA mit voller Zustimmung zur therapeutischen Verwendung.Footprint-freie proprietäre RNA-Reprogrammierung zur Erzeugung von StemRNA™ Clinical iPSC Seed Clones gemäß FDA/EMA/PMDA-Anforderungen.In den USA erzeugte klinische StemRNA
More news about: REPROCELL USA
Mar 03, 2026, 08:01 ET TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license
More news about: TransCode Therapeutics, Inc.
Mar 03, 2026, 07:00 ET SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
e-PRIME recognition underscores potential of inhaled RNA therapy to address unmet need in patients with the 3849+10Kb C>T mutationCompany advancing SPL84 to Phase 2b clinical studyJERUSALEM, March
More news about: Splisense
Mar 02, 2026, 16:19 ET Skyhawk gibt bekannt, dass die australische Arzneimittelbehörde festgestellt hat, dass SKY-0515 zur Behandlung der Huntington-Krankheit die Zulassungskriterien für den vorläufigen Zulassungsweg erfüllt
die das Fortschreiten der Krankheit verlangsamen oder aufhalten.2SKY-0515 ist ein niedermolekularer RNA-Splicing-Modifikator, der im Rahmen von Skyhawks neuartiger RNA-Splicing-Plattform SKYSTAR® entwickelt wurde.SKY-0515 ist das erste Skyhawk-Medikament in klinischen
More news about: Skyhawk Therapeutics
Mar 02, 2026, 10:31 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
approved disease-modifying treatments which slow or halt disease progression.2SKY-0515 is a small molecule RNA splicing modifier developed through Skyhawk's novel RNA-splicing platform, SKYSTAR®.SKY-0515 is the first Skyhawk drug in clinical trials.Skyhawk is developing
More news about: Skyhawk Therapeutics
Mar 02, 2026, 10:29 ET XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
developed using ReviR's proprietary VoyageR AI platform in collaboration with XtalPi's AI+robotics drug discovery engine. By leveraging deep insights into RNA biology and protein translation homeostasis, RTX-117 is designed to act on the Integrated Stress Response (ISR) pathway by activating eIF2B, a mechanism
More news about: XtalPi
Mar 02, 2026, 10:22 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
approved disease-modifying treatments which slow or halt disease progression.2SKY-0515 is a small molecule RNA splicing modifier developed through Skyhawk's novel RNA-splicing platform, SKYSTAR®.SKY-0515 is the first Skyhawk drug in clinical trials.Skyhawk is developing
More news about: Skyhawk Therapeutics
Mar 02, 2026, 09:00 ET ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare and genetic diseases, today announced a pivotal clinical and dual regulatory milestone: the first participant
More news about: ReviR Therapeutics
Mar 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for March 2026
www.xtalks.com to see our upcoming webinars:CELL AND GENE THERAPYMar 12 - How to Build a Measurable Evidence Engine for Cell, Gene and RNA TherapiesCLINICAL TRIALSMar 4 - Accelerate Your Study: Harnessing AI and Automation for Rapid Study Start-upMar 10 -
More news about: Xtalks